Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Orexin Receptor Antagonist (OX1R and OX2R) | Small molecule | Neurological disease | Insomnia Disorder | Phase III | Global (except China) |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
OX2-M82F3 | Mouse | Biotinylated Mouse CD200 / OX-2 Protein, Fc,Avitag™ (MALS verified) |
|
|
|
OX2-H82F1 | Human | Biotinylated Human CD200 / OX-2 Protein, Fc,Avitag™ |
|
|
|
OX2-H5228 | Human | Human CD200 / OX-2 Protein, His Tag |
|
|
|
OX2-H5251 | Human | Human CD200 / OX-2 Protein, Fc Tag |
|
|
Immobilized Human CD200 R1, His Tag (Cat. No. CR2-H52H6) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD200, Fc,Avitag (Cat. No. OX2-H82F1) with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Biotinylated Mouse CD200, Fc,Avitag (Cat. No. OX2-M82F3) is more than 90% and the molecular weight of this protein is around 125-135 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
P-006 | P-006; 23ME-610; 23ME-00610 | Phase 2 Clinical | 23andme Inc | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Neuroendocrine Tumors; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota, OX2 Therapeutics | Glioblastoma; Glioma | Details |
P-006 | P-006; 23ME-610; 23ME-00610 | Phase 2 Clinical | 23andme Inc | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Neuroendocrine Tumors; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota, OX2 Therapeutics | Glioblastoma; Glioma | Details |
This web search service is supported by Google Inc.